Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Active IgG4-RD~* Compatible pattern of organ involvement consistent with IgG4-RD that cannot be attributed to other causes~* Histopathologically-proven diagnosis of IgG4-RD~* Peripheral blood plasmablast count \>900 cells/mL and/or elevated IgG4-RD levels during screening~* Able and willing to complete the entire study according to the study schedule~* Able and willing to provide written informed consent~Exclusion Criteria:~* History or evidence of a clinically unstable/uncontrolled disorder, condition or disease other than IgG4-RD that, in the opinion of the Investigator would pose a risk to the patient safety or interfere with the study evaluation, procedures or completion~* Malignancy within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin, or prostate cancer with no recurrence ≥3 years following prostatectomy)~* Presence of recurrent or chronic infections, defined as ≥3 infections requiring antimicrobials over the past 6 months prior to screening~* Active infection requiring hospitalization or treatment with parenteral antimicrobials within the 60 days prior to randomization or oral antimicrobials within the 21 days prior to enrollment~* Patient is taking \>40 mg of prednisone QD~* Prior use of rituximab (or other B cell depleting agents) within 6 months of enrollment. Prior use of any B cell depleting agent greater than 6 months from enrollment is allowed if the CD19+ B cell count is within the normal reference range during screening~* Use of any investigational agent within 5 half-lives of the agent (or 6 months if the half-life is unknown) prior to enrollment~* Immunosuppressive agent use within the three months prior to enrollment~* Has received live vaccines within 2 months of enrollment~* Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to end-of-study visit~* Unable or unwilling to partake in the follow-up assessments or required protocol procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- XmAb5871 (Type: EXPERIMENTAL): XmAb5871 administered by IV infusion for up to a total of 12 infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).